HomeTrialNCT04287621
🔬NCT04287621ACTIVE NOT RECRUITING

Registry of Asthma Patients Initiating DUPIXENT®

Study Summary

The primary objective of the study is to characterize the patients who initiate treatment for asthma with DUPIXENT® in a real-world setting to understand the attributes of treated patients in real life. This includes characterization of: * Patient demographics (eg, gender, age, and race) * Patient baseline characteristics (eg, prior medications and procedures, medical history, asthma history, weight, height) The secondary objectives of the study are: * To characterize real-world use patterns of DUPIXENT® for asthma * To assess the long-term effectiveness of DUPIXENT® in asthma patients in a real-world setting * To assess effectiveness on comorbid type 2 inflammatory conditions in asthma patients treated with DUPIXENT® * To collect long-term safety data on study participants in the real-world setting

Conditions
Interventions / Drugs
View on ClinicalTrials.gov ↗
Study Details
Enrollment718 participants
Primary Completion
Lead SponsorRegeneron Pharmaceuticals
Data Retrieved2026-04-11 02:55:54.865974+00:00
Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.